Bharat Biotech's Covaxin cleared for 6-12 age group by drugs regulator DCGI, as per media reports
Director-Government and Regulatory Affairs at Serum Institute of India (SII) Prakash Kumar Singh had submitted an application to the DCGI on February 21,...
DCGI on January 27 allowed Bharat Biotech to conduct phase-3 randomised multi-centric clinical study to evaluate immunogenecity and safety of its intranasal...
DCGI's approval came after the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) recommended granting...
Chouhan also sought the participation of the elected representatives, volunteers and religious leaders to encourage children to get vaccinated. The vaccination...
Corbevax has completed two Phase III clinical trials involving more than 3000 subjects between the ages of 18 and 80 at 33 study sites across India.
The government had recently permitted the export of 2 crore doses of COVID-19 vaccine Covovax to Indonesia produced in India by SII, as the jab had not yet...
The Covovax/Novavax vaccine has recently received Emergency Use Listing (EUL) with the World Health Organisation (WHO), Emergency Use Authorization (EUA) in...
On Saturday afternoon, Sushma Hooda tweeted that she is requesting the prime minister "with great hope" to intervene and ensure early approval and purchase of...
.png)
Mahima Datla, Managing Director, Biological E. Limited, said these approvals would help support its subsequent filings with the World Health Organization (WHO)...
The company's indigenously developed needle-free three-dose COVID-19 vaccine ZyCoV-D was granted emergency use authorisation (EUA) by the drug regulator on...
Previously, India's central drug authority's expert panel sent recommendations for the vaccine's EUA to the Drugs Controller General of India (DCGI) for final...